The Alzheimer's Diagnosis Dilemma: Why Doctors Disagree on Defining the Disease
A growing controversy in the medical community is highlighting significant disagreements over how to properly diagnose Alzheimer's disease. Divergent diagnostic criteria are raising serious concerns that some patients are being misdiagnosed and unnecessarily treated with powerful medications that carry potential health risks.
The Diagnostic Divide
Imagine being in your late 60s and receiving an Alzheimer's diagnosis. You might begin planning for long-term care, discussing future incapacity with loved ones, and rushing to complete life goals. Now imagine discovering six months later that another neurologist finds no evidence of Alzheimer's disease. This scenario is becoming increasingly common due to conflicting approaches to diagnosis.
The core debate centers on a fundamental question: How should Alzheimer's disease be defined? Is it purely a biological disease determined by the presence of specific brain proteins, or should diagnosis involve a more complex assessment that includes cognitive symptoms and risk factors?
Conflicting Medical Guidelines
The Alzheimer's Association's 2024 criteria requires evidence of amyloid protein in the brain for diagnosis. In contrast, the International Working Group—a global consortium of neurologists and researchers—demands three elements: the presence of amyloid, tau (another Alzheimer's biomarker), and cognitive symptoms.
Dr. Gayatri Devi, director of Park Avenue Neurology in New York City, reports seeing an increasing number of patients who were incorrectly diagnosed with Alzheimer's over the past year. She describes one case involving a human-resources executive who received an erroneous Alzheimer's diagnosis based on a faulty PET scan showing amyloid presence and his own memory concerns after missing an important meeting.
"That's why we need to be really cautious in giving someone a diagnosis," says Dr. Devi, who recently published an opinion piece in the Annals of Internal Medicine outlining concerns about the different diagnostic criteria. "Many people who are worried about prevention will go for testing. A lot of us have memory issues. We are all multitasking. So symptoms are difficult to define and difficult to self-assess."
The Amyloid Controversy
While the Alzheimer's Association criteria define the disease by amyloid pathology in the brain, they specify that testing and treatment should only occur if a patient exhibits cognitive symptoms. However, doctors like Devi argue this guideline isn't always followed in practice.
Research indicates that approximately 25% to 45% of seniors without memory complaints have amyloid in their brains, and most never develop dementia. "Medicalizing everyone with amyloid in their 70s and 80s is a problem," Devi emphasizes.
Dr. Clifford Jack, a radiologist and professor at Mayo Clinic in Rochester, Minnesota, and first author of the Alzheimer's Association criteria, explains that amyloid serves as a reliable proxy for tau. Current tests for amyloid aren't sensitive enough to detect minimal plaques, meaning when a PET scan or spinal tap shows positive for amyloid, tau tangles are almost certainly present as well.
"Symptoms of Alzheimer's disease typically don't surface until about 15 years after amyloid and tau is detectable in the brain," says Jack. "So of course symptoms are a feature of the disease, but they don't define the presence of the disease."
Treatment Risks and Psychological Impact
Monoclonal antibodies approved for early Alzheimer's treatment carry risks of brain hemorrhages and bleeds. Clinical trials are ongoing to determine whether asymptomatic individuals with amyloid could benefit from these medications, but until results are conclusive, experts like Jack recommend against testing or treating people without symptoms.
Dr. Richard Isaacson, a preventive neurologist at the Institute for Neurodegenerative Diseases in Florida and Atria Health and Research Institute in New York, argues that different definitions are leading to grossly inflated estimates. "You can't diagnose 47 million Americans with Alzheimer's disease," he states. "These Americans have biological markers of Alzheimer's disease risk starting in their brain and detectable in their blood. It doesn't mean all 47 million Americans have a stigmatizing diagnosis like Alzheimer's."
Isaacson strongly disagrees with defining Alzheimer's as purely biological, noting that the disease manifests in various ways. Some patients may have tau without amyloid, while others have amyloid without tau. He compares it to having high cholesterol—it doesn't guarantee a heart attack will occur.
The Semantics of Disease Versus Risk
Dr. David Wolk, a neurologist and director of the University of Pennsylvania's Disease Research Center, suggests the debate ultimately comes down to semantics: having a disease versus being at risk for it. The danger of relying solely on cognitive symptoms and amyloid, he notes, is that not all physicians thoroughly investigate alternative causes for cognitive issues.
"It wouldn't surprise me if there are some patients who are receiving these medicines and have Alzheimer's biology but it may not be a cause of their symptoms," Wolk observes.
Dr. Reisa Sperling, a neurology professor at Harvard Medical School who conducts studies testing anti-amyloid drugs in asymptomatic individuals, advocates for early intervention. She criticizes the International Working Group's requirement for cognitive impairment, comparing it to waiting until someone with diabetes develops blindness or kidney failure before diagnosis.
"All disease begins before symptoms, and most diseases are better treated before people walk into your office with clear impairment," Sperling argues.
Moving Forward with Caution
Dr. Devi emphasizes the profound psychological impact of receiving an incorrect Alzheimer's diagnosis. Until the medical community reaches greater consensus on both early diagnosis and treatment effectiveness, she advises patients to avoid unnecessary testing—particularly with the increasing availability of easily accessible blood tests.
The ongoing debate highlights the complex nature of Alzheimer's disease and underscores the need for more precise diagnostic tools and unified medical guidelines to prevent misdiagnosis and ensure appropriate patient care.
